Clinical application of RUBCN/SESN2 mediated inhibition of autophagy as biomarkers of diabetic kidney disease

Table 4 Linear regression analysis test results for evaluation of the ability of serum RUBCN, serum SESN2, serum mTOR, RUBCN mRNA expression and SESN2 mRNA expression to predict nephropathy in diabetic patients

Model	Unstandardized coefficients		Standardized coefficients	t	Sig
Model	B	Std. Error	Beta	t	Sig
(A) simple linear regression analysis
(Constant)	− 77.284	9.729		− 7.944	< 0.001*
Serum RUBCN	62.049	2.350	0.925	26.403	< 0.001*
(Constant)	582.634	28.636		20.346	< 0.001*
Serum SESN2	− 71.858	4.442	− 0.830	− 16.177	< 0.001*
(Constant)	− 73.796	13.168		− 5.604	< 0.001*
Serum mTOR	63.356	3.348	0.867	18.922	< 0.001*
(Constant)	− 57.630	7.626		−7.557	< 0.001*
RUBCN expression	45.475	1.429	0.946	31.820	< 0.001*
(Constant)	368.818	12.238		30.136	< 0.001*
SESN2 expression	− 393.326	17.878	− 0.897	− 22.001	< 0.001*
(B) multiple linear regression analysis
(Constant)	91.198	68.350		1.334	0.185
Serum RUBCN	27.094	5.557	0.407	4.876	< 0.001*
Serum SESN2	3.044	5.619	0.153	1.580	0.09
Serum mTOR	19.946	6.550	0.273	3.045	0.003*
RUBCN expression	12.926	3.791	0.274	3.409	< 0.001*
SESN2 expression	− 103.833	43.678	− 0.238	− 2.377	0.019*

Dependent variable: Albumin/creatnine ratio
^*Indicates statistical significance
RUBCN: Rubicon; SESN2: Sestrin-2; mTOR: mammalian target of Rapamycin
Multiple regression test was used to assess the ability to predict Albumin/creatnine ratio based on the level of serum RUBCN, serum SESN2, serum mTOR, RUBCN mRNA expression and SESN2 mRNA expression

ISSN: 1528-3658